FDA Requests Comments on Planned 503B List Study

Drug Industry Daily
A A
The FDA Friday issued a comment request on obtaining information for evaluating bulk drug substances for use in drug compounding.

To View This Article:

Login

Subscribe To Drug Industry Daily